As the GLP1 therapy landscape shifts in 2026, clinical success is being redefined by more than just numbers on a scale. Join Dr. Sean Wharton for an essential update on the diversification of the GLP-1 market, including the impact of new therapeutic entries on patient access. This session moves beyond weight-centric management to explore the systemic, multi-organ benefits of GLP-1s, providing a blueprint for achieving total metabolic health and long-term quality of life in your patients.
GLP-1: Navigating New Agents and Total Metabolic Health with Dr. Sean Wharton
CAN-eng
$0
gratuit
Non accrédité
1 heure
Diabetes,Obesity
0 Crédits
Description du cours
Détails du cours
Date d'expiration : 2027-07-10
Métiers: Physician,Nursing,Pharmacy,Allied Health,Medical Resident,Student,Specialist
Faculté
- Sean Wharton, MD, FRCPC, PharmD, General Internal Medicine, Obesity Medicine
Accréditation
Objectifs d'apprentissage
After viewing this webinar, participants will be better able to:
- Advance the Science of Obesity Management
Evaluate the latest clinical data on incretin therapies and the biological mechanisms that drive weight regain and obesity. - Navigate the Expanding Therapeutic Landscape
Analyze the clinical role of new and emerging agents, including the impact of increased market options on patient access and treatment selection. - Redefine Clinical Goals in Obesity Medicine
Discuss the shift from weight-centric metrics toward holistic outcomes, focusing on metabolic health and long-term quality of life.